Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL7201308

CCCc1nn2cccnc2c1CCC.N

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 2/20 0.40
USP2 O75604 1/20 0.37
JAK2 O60674 1/20 0.36
JAK3 P52333 1/20 0.36
SMPD3 Q9NY59 2/20 0.35
PDE10A Q9Y233 1/20 0.35
AXL P30530 1/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
HTR6 P50406 4/20 0.33
MYC P01106 1/20 0.33
HPGD P15428 1/20 0.33
ALDH1A1 P00352 1/20 0.32
APOBEC3A P31941 1/20 0.32
CDK2 P24941 1/20 0.32
PDE2A O00408 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formamide SCHEMBL7067260 0.90 USP2 (0.36) PIK3CGUSP2JAK2JAK3SMPD3
SCHEMBL15020746 0.84 PIK3CG (0.41) PIK3CGJAK2JAK3SMPD3AXL
SCHEMBL9741997 0.74 ALDH1A1 (0.38) HPGDALDH1A1APOBEC3A
Ammonia Solution, Strong SCHEMBL6629978 0.72 HDAC1 (0.41) USP2PDE4APDE4BPDE4CPDE4D
SCHEMBL15308545 0.71 PIK3CG (0.54) PIK3CGJAK2JAK3SMPD3AXL
SCHEMBL18622279 0.71 PIK3CG (0.46) PIK3CGJAK2JAK3SMPD3AXL
SCHEMBL38666729 0.70 SMPD3 (0.43) PIK3CGJAK2JAK3SMPD3AXL
SCHEMBL16646749 0.70 JAK2 (0.46) PIK3CGJAK2JAK3SMPD3PDE2A
SCHEMBL25317207 0.67 NOS2 (0.42) USP2PDE10APDE4APDE4BPDE4C
SCHEMBL30410343 0.66 SMN1; SMN2 (0.41) PIK3CGJAK2JAK3HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010041673-A1 Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues PFIZER INC. 2001-11-15 US claimed
US-6589947-B1 Treatment or prevention of Syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist alone or together with a glucocorticoid receptor antagonist. PFIZER INC. 2003-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010041673-A1 Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues CRH, GHSR, GHRHR PIK3CG 3857/4885USP2 1006/4885JAK2 1381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.